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Stroke is a major cause of death and long-term disability world-wide. To improve functional outcome treatment 
with intravenous tissue plasminogen activator (tPA) is the most effective medical treatment for acute brain 
infarction within 4.5 hours after the onset of stroke symptoms. Unfortunately, tPA remains substantially 
underutilized. Acute stroke care organization is among the dominant factors determining undertreatment. 
Recently, simulation has been suggested and successfully implemented as a tool for optimizing stroke care 
pathway logistics. Starting from a number of pioneering simulation studies challenges in simulation application 
and simulation methodology are identified. The definition of a domain specific modelling framework for acute 
stroke care is advocated to master system complexities, facilitate joint team work in solution finding, organize 
model data collection and make a further entrance to the field. 
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1 INTRODUCTION 
Acute ischemic stroke is the second leading cause of death and a leading cause of long-term disability 
world-wide (Truelsen et al., 2005; WHO, 2012). The acute brain infarction is caused by a blood clot. 
As a result of the blocked blood vessel downstream brain tissue is deprived from oxygen and starts to 
mortify. The longer the blood clot is existent the more damage is done, resulting in (severe) disability 
and possibly death. 
Treatment with intravenous tissue plasminogen activator (tPA) is the most effective medical 
treatment for acute brain infarction. Essentially, tPA restores blood flow in the brain by dissolving the 
blood clot at the root of infarction. tPA has shown to be effective, i.e., improving patient functional 
outcome, within 4.5 hours after the onset of stroke symptoms. Of all patients worldwide suffering a 
stroke, 1–8% (Wardlaw et al., 2009; Adeoye et al., 2011; Singer et al., 2012) are currently treated with 
tPA, whereas 24–31% (Waite et al., 2006; Boode et al., 2007) would be attainable in optimized settings. 
The sooner the treatment is started the better functional outcome is i.e. TIME = BRAIN. 
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Main causes of undertreatment found are the narrow therapeutic time window, patient and 
bystander unfamiliarity with stroke symptoms and how to act, and stroke care organization. Notably, 
the benefit of tPA depends strongly on time since stroke onset (The National Institute of Neurological 
Disorders and Stroke rtPA Stroke Study Group, 1995; Hacke et al., 2008; Lees et al., 2010; Wardlaw 
et al., 2012; Emberson et al., 2014), which in turn negatively affects the chance of administering tPA 
treatment as time since onset increases (Hamann, 2004). 
In recent years many researchers made proposals for improving stroke care organization, thereby 
attempting to reduce patients’ delay along the stroke pathway, and – hence – increase their chances for 
favourable outcomes. Respective research efforts have primarily relied on the use of Randomized 
Controlled Trials (RCTs) as a main research vehicle. RCTs are meant to establish potential benefits of 
alternative set-ups of the stroke pathway, by comparing real-life outcomes for two groups of patients: 
those that traversed the existing pathway and those for whom the pathway has been adapted according 
to proposed interventions. Although the merits of RCTs for use in health research concerning simple or 
solitary interventions such as pharmaceuticals or devices are clearly established, complexity of the acute 
stroke pathway – entailing a sequence of interrelated care services, spanning both the pre-hospital and 
the hospital phase – may hinder its applicability. For example, two recently proposed improvement 
programs reported disappointingly low nonsignificant increases in tPA treatment rate of 1.0–1.5% 
(Dirks et al., 2011; Scott et al., 2013). Clearly, disadvantages of real-life testing in terms of time, costs 
and efforts involved in study set-up and experimenting, and project organization, management and lead 
time become apparent here (Law, 2007). 
Recently, several studies have shown how simulation may be used as an efficient alternative or 
precursor to clinical trials (Monks et al., 2012; Pitt et al., 2013; Churilov et al., 2013; Lahr et al., 2013a; 
Lahr et al., 2013c; Jacobson et al., 2015; Komenda et al., 2015). Whereas clinical trials are limited to 
testing a seemingly arbitrarily selected set of interventions along the stroke pathway, the efficiency of 
computer simulation models allows for a far greater set of interventions to be put to test at minimum 
efforts and means. Moreover, where efforts in setting up clinical trials often restrict studies to just a part 
of the stroke pathway, simulation can easily cope with interventions addressing the entire stroke 
pathway. Furthermore, simulation efficiency does not only allow for redesigning existing stroke 
pathways but also rethinking the way care chains may be set-up for a region. For example, should stroke 
care be offered at every community hospital (i.e. decentralize facilities), or should care be concentrated 
in a comprehensive stroke center (i.e. centralize facilities)? 
 Apart from aforementioned efforts simulation hardly made an entrance in the field. In this article 
we identify and study modelling challenges faced in addressing the field, thereby relying on our 
experiences in doing some of the pioneering studies for the field (Monks et al., 2012; Pitt et al., 2013; 
Lahr et al., 2013a; Lahr et al., 2013c). Our findings are meant to accelerate studies in the field (i) by 
identifying hurdles – and ways to overcome these – for those who consider undertaking simulation 
studies, and (ii) reveal research requirements for simulation modelling methodology. 
 The remainder of the paper is organized as follows. In Section 2 we shortly typify the hyper acute 
stroke pathway. In Section 3, we address challenges faced in simulation application, concerning 
complexities in system design, innovations impacting future system design, and project organization. 
Next, in Section 4 we address methodological challenges faced in simulation use for stroke system 
optimization. Finally, we will discuss and summarize main findings (Section 5 and 6). 
2 STROKE SYSTEMS – THE HYPER ACUTE PATHWAY 
Stroke is categorized in two sub types: ischemic and hemorrhagic, relating to about 85% and 15% of 
the patient population respectively. Ischemic strokes occur when a blood vessel is blocked due to a clot 
and disrupts blood circulation to the brain, whereas hemorrhagic strokes boil down to a bleeding. Only 
ischemic strokes are eligible for tPA treatment, see Section 1. 
 The stroke pathway entails several phases. Here we only consider the initial phase, the so-called 
hyper acute (emergency) phase, see Figure 1. The hyper acute phase spans care services from stroke 
onset to tPA treatment. Patients either arrive at the hospital by Emergency Medical Services (EMS) 
after making a call to their GP or the emergency number (112) or by self-referral. Next, a patient’s 
eligibility for tPA treatment depends on his/her delay along the pathway (treatment must be 
administered within < 4.5 hours of the onset of symptoms) together with the results from the 
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neurological examination, laboratory evaluation (blood testing) and neuroimaging examination (CT-
scanning). tPA treatment influences patient outcomes in terms of the severity of their disabilities, 
ranging from no disabilities, to major disabilities or death. Note that a small number of the patients 




























Figure 1 Hyper acute stroke pathway – dominant set-up 
3 CHALLENGES IN SIMULATION APPLICATION 
Until a few years ago hardly any simulation study had been performed for optimizing the hyper acute 
stroke pathway. Below we address modelling challenges encountered in our recent studies (Monks et 
al., 2012; Pitt et al., 2012; Lahr et al., 2013a; Lahr et al., 2013c). Challenges will be linked to system 
complexities, system innovation, performance measurement and project characteristics. 
3.1 System Design 
Where RCTs only allow for studying a small set of interventions along the stroke pathway, simulation 
efficiencies enable elaborate testing of more complex systems. Observed opportunities for simulation 
use are in decision support for operational decision making – focusing at the overall chain optimization 
of existing treatment chains, and strategic decision making – concerning the choice of the regional 
stroke system network topology. The first opportunity is in line with a growing awareness in the field 
that a concerted effort of all parties involved in the hyper acute pathway results in best chain 
performance, i.e., highest treatment rates and best outcomes. Whereas earlier research efforts 
concentrated on optimizing the intra-hospital phase, relevance of including the pre-hospital phase in 
overall chain optimization has been widely acknowledged in recent years (Fassbender et al., 2013). The 
second opportunity relates to the observed need for a regional organization of care, for reasons of health 
economics and health quality, i.e., patient outcomes. For example, it has been shown how concentrating 
treatment of acute stroke in comprehensive stroke centres, instead of attending to patients in the nearest 
community hospital may benefit patients (Lahr, 2013; Lahr et al., 2013b). Clearly, such choices with 
respect to regional organization of stroke care suggest a trade-off between transport delays in the pre-
hospital phase vs. potentially better care and shorter lead times for the comprehensive stroke centre 
(Monks et al,. 2014). 
3.2 System Innovation 
Whereas opportunities sketched in Section 3.1 essentially do not question pathway set-up in terms of 
the nature of care services, recent innovations do so. We observe two avenues of future change, 
concerning health technology employed in patient diagnosis, and new treatments. As far as technology 
is concerned we mention the following examples:  
 The Point of Care device, allowing for a quick analysis of patient blood samples – as a replacement 
of classic blood testing as done in a lab (Rizos et al., 2009). 
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 Telemedicine, suggesting to exploit communication devices for, for example, consulting stroke 
expertise at a distance for use on scene or in a hospital lacking suchlike expertise, or pre-notifying 
patient arrivals at the hospital (Levine and Gorman, 1999). 
 Mobile scanning technology available in the ambulance, allowing for CT-scanning at the patient 
scene. Note that this concept is exploited by so-called Mobile Stroke Units, i.e., dedicated 
ambulances that allow for tPA treatment at the patient scene (Wendt et al., 2015). 
Note that all aforementioned examples stress reduction of delays along the stroke pathway.  
 Furthermore, we mention emerging new treatments for acute stroke. Recently, the use of 
endovascular thrombectomy (mechanical clot retrieval using a medical device) has been shown to 
improve patient outcomes (Berkhemer et al., 2014). Although its benefits are clear, it comes at a price, 
by setting specific demands concerning stroke expertise, and scanning technology (CTA-scanning). 
This may imply that in the near future it may only be offered by comprehensive stroke centres. 
3.3 Performance Measurement 
Interestingly, recent stroke studies have shown the linkage of treatment effectiveness in terms of patient 
outcomes and logistic performance, i.e., patient delay from stroke-onset to his/her treatment. Recent 
research shows how outcomes for acute stroke patient in terms of his/her chances of being treated (Lahr, 
2013a), disabilities (Lees et al., 2010), and additional life years gained (Meretoja et al., 2014), may be 
estimated as a function of the patient treatment lead time. In turn, patient outcomes may be used to 
assess cost-effectiveness of alternative set-ups of the hyper acute stroke pathway. 
3.4 Project Characteristics 
Simulation studies on stroke systems tend to put high requirements on project team composition. 
Typically, the team hosts parties involved in the pathway, i.e., neurologists, EMS and GPs, health 
economists, health system engineers and simulation modellers. Profound insights on the way 
(interlinked) care services influence patient outcomes and the way chain logistics may be best 
organized, modelled and analysed are the key stones of a successful simulation study. Project efforts 
should be concentrated on creating a mutual understanding of stroke system set-up to facilitate its joint 
(re)engineering. Such an understanding is not guaranteed as parties, and disciplines represented in the 
team, may not be familiar with such co-operation. 
4 CHALLENGES IN SIMULATION MODELLING METHODOLOGY 
How to facilitate the simulation modeller and his team in setting up and doing the study? Here we 
explore methodological issues as they relate to the problem situation, and current means for addressing 
them. 
4.1 Problem Situation 
Optimization of the hyper acute stroke pathway is considered a world-wide issue. This is due to the 
number of patients involved (estimated at 15 million per year worldwide), and the severity of health 
consequences faced by those patients not being treated (as they arrive not within the therapeutic time 
window or the hospital is unable to treat them within 4.5 hours of onset) or who could have been treated 
earlier within the therapeutic time window – thereby improving their chances on favourable outcomes. 
In principle, care services along the hyper acute pathway required for effective tPA treatment are rather 
well-known. However, their implementation and facilitation (staffing, resources, and their co-ordinated 
use) may differ from country to country or even from region to region, due to the way local health 
infrastructures have been set-up. Nevertheless, world wide similarities in both choice of care services 
and system set-up suggest a high potential for simulation model re-use. 
 The hyper acute pathway is a complex system. Relevant parties in set-up and operation of the hyper 
acute stroke pathway include not only care givers, such as GPs, EMS, and neurologists, but also those 
who fund or regulate stroke care, such as insurance companies, (local) governments, and professional 
societies, and – last but not least – (representatives of) patients. This clarifies the need for problem 
structuring, to get a joint hold of system set-up and problems faced in optimizing it. In turn, this may 
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also provide initial guidance on (conceptual) modelling – by revealing possibilities for model 
simplification. 
 For a simulation study to be successful (historical) data on patient lead times, diagnostic results, 
and their treatment and its outcomes are crucial, both to facilitate model set-up and its validation. 
Ideally, the build up of patient lead time along the hyper acute pathway since stroke onset can be 
explained by sufficient data on relevant care services. In turn, diagnostic results, like patient’s choice 
of first responder, EMS urgency level etc. will inform patient routings. Finally, data on patient treatment 
captures their likeliness of being treated, and their expected outcomes. Unfortunately, in many cases 
respective categories of data may (i) not be easily accessed as they are dispersed over separate parties 
involved in the hyper acute pathway or (ii) may not be available altogether, and have to be obtained at 
high costs. 
 Typically, as simulation is new for the field, aforementioned parties involved in optimizing stroke 
systems are not familiar with simulation. This implies a need to familiarize them with the tool, its 
application, and its potential for decision support on stroke system design. 
4.2 Guidance Available 
How should we address the challenges faced in the problem situation, as identified in Section 4.1? Many 
challenges link to the initial phases of a simulation study, i.e., conceptual modelling. So far, model 
coding, and its analysis, seem to be less of an issue. Note that this does not imply that they may not 
become a future issue. 
 Three basic approaches may be distinguished for guiding the analyst in specifying a conceptual 
model for simulation (Robinson, 2008a). Principles of modelling advocate the benefits of aiming for 
simple models through incremental modelling. Their application may, among others, entail the good 
use of metaphors, analogies, and similarities in model creation (Pidd, 1999). Methods of simplification 
work the other way around by suggesting a reduction of model scope and detail. Gains with respect to 
modelling efforts or computational efficiencies in doing experiments may be realized by, for example, 
combining model elements, leaving them out or adapting their attributes (Innis and Rexstad, 1983). 
Modelling frameworks suggest a step wise approach for detailing the conceptual model in terms of its 
elements, their attributes and their relationships. Typically, proposed steps are supported by guidelines, 
methods, and good practices. 
 The main differences among modelling frameworks concern their intended field of application, 
scope, and process support. Modelling frameworks developed so far tend to address rather broad fields 
of application, like operations systems (Robinson, 2008b), supply chains (Van der Zee and Van der 
Vorst, 2005), health systems (Kotiadis, 2007), and the military (Pace, 1999; Pace, 2000). Whereas some 
frameworks restrict scope to the specification of model content only (Arbez and Birta, 2011), other 
frameworks include problem understanding, modelling objectives, experimental factors and model 
responses (Kotiadis, 2007; Robinson, 2008b). Chwif et al. (2013), and Kotiadis et al. (2014) address 
process support by suggesting formats for workshops, conceptual model documentation and the way 
model data are to be collected. For overviews of modelling frameworks, see Robinson (2008a), Karagoz 
and Demirors (2011), and Van der Zee et al. (2011). 
 Clearly, aforementioned approaches indicate relevant support for simulation conceptual modelling. 
However, they usually do not inform and guide the analyst in addressing modelling needs that are 
specific for a branch of industry or a domain of health care. 
5 DISCUSSION 
Challenges faced in simulation-based optimization of the hyper acute stroke pathway indicate that 
developing conceptual frameworks may be worthwhile, in an attempt to master system complexities, 
facilitate joint team work in solution finding, organize model data collection and make a further entrance 
to the field. Problem scale, and similarities in system set-up suggest that efforts put in defining such 
frameworks are relevant and feasible. Moreover, a domain specific framework would present an 
interesting – potentially viable – example of simulation model re-use. Re-use would build on the 
identification of generic model components, solution directions (model inputs), and relevant 
performance measures (model outputs), and ways of exploiting such means in process set-up and data 
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collection. Clearly, defining such a framework is no easy job, already because it involves the 
involvement of many parties and disciplines. 
6 CONCLUDING REMARKS 
In this article we identify and study simulation modelling challenges faced in addressing the hyper acute 
stroke pathway. In doing so, we rely on our experiences in performing some of the pioneering studies 
for the field. We found how many challenges seem to address simulation conceptual modelling. The 
definition of a domain specific modelling framework for acute stroke care is advocated in an attempt to 
master system complexities, facilitate joint team work in solution finding, organize model data 
collection and make a further entrance to the field. Apart from being highly relevant for the field, given 
patient numbers, and potential for improving their health, the framework may present an interesting 
example of simulation model re-use. In our future work we will address the definition and use of such 
a framework.  
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